Advertisement

Topics

Daiichi Sankyo pulls plug on Coherus biosimilar

05:27 EDT 5 Jul 2017 | BioPharmaDive

The Japanese company said it would no longer develop the Enbrel biosimilar in Japan — leaving Coherus without any pharma backers for the copycat biologic. 

Original Article: Daiichi Sankyo pulls plug on Coherus biosimilar

NEXT ARTICLE

More From BioPortfolio on "Daiichi Sankyo pulls plug on Coherus biosimilar"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...